交互式炎症性肠病生物制剂决策辅助工具与静态教育相比未改善患者结局:随机试验结果
这项多中心比较效果试验将152例有近期症状且希望讨论生物制剂的炎症性肠病患者随机分入IBD&me交互式决策辅助组(77例)或克罗恩病与结肠炎基金会生物制剂事实表组(75例),发现两组在共享决策评分上无显著差异(事实表72.6±25.6 vs IBD&me 75.0±20.8,P=0.57),患者对两种资源的推荐意愿均较高。
要点
- IBD&me交互式决策辅助与事实表在共享决策评分上无显著差异(P=0.57)。
- 多数患者表示可能向其他IBD患者推荐事实表(79.6%)或IBD&me(84.9%),P=0.48。
- 作者认为需进一步研究,尤其在生物制剂初治患者中,以确定交互式组件对IBD决策辅助工具的效用。
核心结论
- 在这项比较效果研究中,IBD&me与生物制剂事实表之间未见结局差异,患者对两种资源均报告高满意度。
- 作者认为需进一步研究,尤其在生物制剂初治患者中,以确定交互式组件对IBD决策辅助工具的效用。
研究设计与样本
- 多中心比较效果试验,在IBD Qorus(多中心成人IBD学习型医疗系统)内的门诊纳入患者。
- 纳入2019年3月5日至2021年5月14日期间有近期IBD相关症状且希望在即将就诊时与提供者讨论生物制剂的患者。
- 采用分层区组随机化按1:1分组,就诊前1周通过电子邮件邀请患者审阅IBD&me或事实表。
- 共随机化152例患者(生物制剂事实表75例,IBD&me 77例)。
主要发现
- 多数患者为克罗恩病(66.4%)且有生物制剂使用经验(82.9%)。
- 共享决策评分(9项共享决策问卷,0-100分,分数越高越好):事实表组72.6±25.6 vs IBD&me组75.0±20.8,P=0.57,两组间无差异。
- 表示可能向其他IBD患者推荐该资源的患者比例:事实表组79.6% vs IBD&me组84.9%,P=0.48。
关键数值与推荐
- 主要结局为患者对共享决策的感知,采用9项共享决策问卷(0-100分,分数越高越好)测量,使用Student t检验比较两组结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需进一步研究,尤其在生物制剂初治患者中,以确定交互式组件对IBD决策辅助工具的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To support shared decision-making (SDM) between patients and providers surrounding biologic treatments, we created IBD&me ( ibdandme.org )-a freely available, unbranded, interactive decision aid. We performed a multicenter comparative effectiveness trial comparing the impact of IBD&me on SDM vs a biologics fact sheet developed by the Crohn's & Colitis Foundation. METHODS: We enrolled patients with inflammatory bowel disease (IBD) being seen at a clinic within IBD Qorus-a multicenter adult IBD learning health system-between March 5, 2019, and May 14, 2021. Eligible patients included those with recent IBD-related symptoms who reported that they wanted to discuss biologics with their provider during their upcoming visit. Patients were randomized 1:1 using stratified block randomization and received an e-mail 1 week before their visit inviting them to review either IBD&me or a fact sheet. The primary outcome was patient perception of SDM as measured by the 9-Item SDM Questionnaire (0-100 scale; higher = better); the Student t test was used to compare outcomes between arms. RESULTS: Overall, 152 patients were randomized (biologics fact sheet 75, IBD&me 77); most patients had Crohn's disease (66.4%) and were biologic-experienced (82.9%). No differences were seen between groups regarding SDM (fact sheet 72.6 ± 25.6, IBD&me 75.0 ± 20.8; P = .57). Most patients stated they would be likely to recommend the fact sheet (79.6%) or IBD&me (84.9%; P = .48) to another patient with IBD. DISCUSSION: No differences in outcomes were seen between IBD&me and the biologics fact sheet in this comparative effectiveness study; patients reported high satisfaction with both resources. Further study, particularly among biologic naïve patients, is needed to determine the utility of interactive components to IBD decision aids.
引用
- Almario CV, van Deen WK, Chen M, et al. Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial. Am J Gastroenterol. 2022. PMID: 35973146. doi:10.14309/ajg.0000000000001866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。